161 related articles for article (PubMed ID: 19940208)
1. Difference between total and intact assays for N-terminal propeptide of type I procollagen reflects degradation of pN-collagen rather than denaturation of intact propeptide.
Koivula MK; Ruotsalainen V; Björkman M; Nurmenniemi S; Ikäheimo R; Savolainen K; Sorva A; Risteli J
Ann Clin Biochem; 2010 Jan; 47(Pt 1):67-71. PubMed ID: 19940208
[TBL] [Abstract][Full Text] [Related]
2. Comparison of total and intact aminoterminal propeptide of type I procollagen assays in patients with breast cancer with or without bone metastases.
Marin L; Koivula MK; Jukkola-Vuorinen A; Leino A; Risteli J
Ann Clin Biochem; 2011 Sep; 48(Pt 5):447-51. PubMed ID: 21733929
[TBL] [Abstract][Full Text] [Related]
3. Measurement of aminoterminal propeptide of type I procollagen (PINP) in serum.
Koivula MK; Risteli L; Risteli J
Clin Biochem; 2012 Aug; 45(12):920-7. PubMed ID: 22480789
[TBL] [Abstract][Full Text] [Related]
4. The amino-terminal propeptide (PINP) of type I collagen is a clinically valid indicator of bone turnover and extent of metastatic spread in osseous metastatic breast cancer.
Pollmann D; Siepmann S; Geppert R; Wernecke KD; Possinger K; Lüftner D
Anticancer Res; 2007; 27(4A):1853-62. PubMed ID: 17649784
[TBL] [Abstract][Full Text] [Related]
5. Type I collagen metabolites as tumor markers in patients with lung carcinoma.
Kobayashi T; Gabazza EC; Taguchi O; Risteli J; Risteli L; Kobayashi H; Yasui H; Yuda H; Sakai T; Kaneda M; Adachi Y
Cancer; 1999 May; 85(9):1951-7. PubMed ID: 10223235
[TBL] [Abstract][Full Text] [Related]
6. [Clinical usefulness of cross-linked N-telopeptide of type I collagen (NTx) as a bone metastatic marker in patients with prostate cancer--comparison with serum PICP, PINP and ICTP].
Kobayashi Y; Ochi M; Tokue A
Hinyokika Kiyo; 2000 Dec; 46(12):869-72. PubMed ID: 11211802
[TBL] [Abstract][Full Text] [Related]
7. Serum concentrations of type I collagen carboxyterminal telopeptide (ICTP) and type I procollagen carboxy-and aminoterminal propeptides (PICP, PINP) as markers of metastatic bone disease in breast cancer.
Tähtelä R; Thölix E
Anticancer Res; 1996; 16(4B):2289-93. PubMed ID: 8694558
[TBL] [Abstract][Full Text] [Related]
8. How useful are bone turnover markers in rheumatoid arthritis? Influence of disease activity and corticosteroid therapy.
Cortet B; Flipo RM; Pigny P; Duquesnoy B; Racadot A; Boersma A; Delcambre B
Rev Rhum Engl Ed; 1997 Mar; 64(3):153-9. PubMed ID: 9090763
[TBL] [Abstract][Full Text] [Related]
9. Vitamin D supplementation to healthy children does not affect serum osteocalcin or markers of type I collagen turnover.
Schou AJ; Heuck C; Wolthers OD
Acta Paediatr; 2003 Jul; 92(7):797-801. PubMed ID: 12892157
[TBL] [Abstract][Full Text] [Related]
10. Validation of an automated intact N-terminal propeptide of type I procollagen (PINP) assay.
Koivula MK; Richardson J; Leino A; Valleala H; Griffiths K; Barnes A; Konttinen YT; Garrity M; Risteli J
Clin Biochem; 2010 Dec; 43(18):1453-7. PubMed ID: 20923676
[TBL] [Abstract][Full Text] [Related]
11. Assessing bone formation in patients with chronic kidney disease using procollagen type I N-terminal propeptide (PINP): The choice of assay makes a difference.
Tridimas A; Milan A; Marks E
Ann Clin Biochem; 2021 Sep; 58(5):528-536. PubMed ID: 34096326
[TBL] [Abstract][Full Text] [Related]
12. A multicenter study to evaluate harmonization of assays for N-terminal propeptide of type I procollagen (PINP): a report from the IFCC-IOF Joint Committee for Bone Metabolism.
Cavalier E; Eastell R; Rye Jørgensen N; Makris K; Tournis S; Vasikaran S; Kanis JA; Cooper C; Pottel H; Morris HA;
Clin Chem Lab Med; 2019 Sep; 57(10):1546-1555. PubMed ID: 31085740
[TBL] [Abstract][Full Text] [Related]
13. Comparison of three serum assays for bone collagen formation during postmenopausal estrogen-progestin therapy.
Suvanto-Luukkonen E; Risteli L; Sundström H; Penttinen J; Kauppila A; Risteli J
Clin Chim Acta; 1997 Oct; 266(2):105-16. PubMed ID: 9437539
[TBL] [Abstract][Full Text] [Related]
14. Assay for cross-linked carboxyterminal telopeptide of type I collagen (ICTP) unlike CrossLaps assay reflects increased pathological degradation of type I collagen in rheumatoid arthritis.
Sassi ML; Aman S; Hakala M; Luukkainen R; Risteli J
Clin Chem Lab Med; 2003 Aug; 41(8):1038-44. PubMed ID: 12964811
[TBL] [Abstract][Full Text] [Related]
15. Circulating levels of collagen type I degradation marker depend on the type of atrial fibrillation.
Tziakas DN; Chalikias GK; Papanas N; Stakos DA; Chatzikyriakou SV; Maltezos E
Europace; 2007 Aug; 9(8):589-96. PubMed ID: 17485436
[TBL] [Abstract][Full Text] [Related]
16. Procollagen I amino-terminal propeptide as a potential marker for multiple myeloma.
Kowalska M; Druzd-Sitek A; Fuksiewicz M; Kotowicz B; Chechlinska M; Syczewska M; Walewski J; Kaminska J
Clin Biochem; 2010 Apr; 43(6):604-8. PubMed ID: 20045402
[TBL] [Abstract][Full Text] [Related]
17. The aminoterminal propeptide of type III procollagen. Studies on physiology and pathophysiology.
Jensen LT
Dan Med Bull; 1997 Feb; 44(1):70-8. PubMed ID: 9062765
[TBL] [Abstract][Full Text] [Related]
18. Preoperative high type I collagen degradation marker ICTP reflects advanced breast cancer.
Keskikuru R; Kataja V; Kosma VM; Eskelinen M; Uusitupa M; Johansson R; Risteli L; Risteli J; Jukkola A
Anticancer Res; 1999; 19(5C):4481-4. PubMed ID: 10650796
[TBL] [Abstract][Full Text] [Related]
19. Short-term changes in serum PINP predict long-term changes in trabecular bone in the rat ovariectomy model.
Rissanen JP; Suominen MI; Peng Z; Morko J; Rasi S; Risteli J; Halleen JM
Calcif Tissue Int; 2008 Feb; 82(2):155-61. PubMed ID: 18219436
[TBL] [Abstract][Full Text] [Related]
20. Bone metabolism markers and ghrelin in boys at different stages of sexual maturity.
Jürimäe J; Pomerants T; Tillmann V; Jürimäe T
Acta Paediatr; 2009 May; 98(5):892-6. PubMed ID: 19243352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
